Method for determining microcystic toxins-LR in human urine through liquid chromatography-mass spectrometry

Through the combined use of liquid chromatography and mass spectrometry, the species difference and sensitivity of microcystoxin-LR detection in urine were solved, and efficient and accurate detection of MC-LR in human urine was achieved, which is suitable for epidemics Study research.

CN118961934AActive Publication Date: 2024-11-15ZHENGZHOU UNIV

Patent Information

Application Number
CN202411115518.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-15
Estimated Expiration
2044-08-14

AI Technical Summary

Technical Problem

The existing microcystis toxin-LR detection methods in urine have problems such as species differences, method specificity and insufficient detection sensitivity, and it is difficult to quickly and accurately detect MC-LR in human urine.

Method used

Using liquid chromatography and mass spectrometry combined technology, the efficient separation and quantitative detection of microcystis toxin-LR in urine is achieved through standard curve establishment and sample processing (including solid phase extraction, vacuum concentration and mass spectrometry analysis).

Benefits of technology

It improves detection sensitivity, meets the precise quantitative needs of MC-LR, and realizes accurate quantification of MC-LR in human urine, has good linear relationships and reproducibility, and is suitable for MC-LR concentration detection in the general population.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961934A_ABST
    Figure CN118961934A_ABST
Patent Text Reader

Abstract

The invention provides a method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry. The method comprises the following steps: preparing a microcystin-LR standard aqueous solution; performing UPLC-MS / MS analysis on the standard aqueous solution; establishing a standard curve of the concentration of the microcystic toxin-LR standard aqueous solution corresponding to the peak area; the method comprises the following steps: treating a urine sample, taking supernate, carrying out solid-phase extraction, respectively leaching with ultrapure water and a methanol aqueous solution, eluting with a high-concentration methanol solution, and drying with nitrogen; redissolving a product obtained by blow-drying the nitrogen by using a pure methanol solution, then performing vacuum concentration, redissolving again by using ultrapure water, taking supernate, and performing UPLC-MS / MS analysis; and calculating the concentration of the microcystic toxins-LR in the urine according to the standard curve according to the peak area corresponding to the microcystic toxins-LR in the urine sample obtained by UPLC-MS / MS analysis. According to the method, the problem of applicability to human urine in an existing treatment method is solved, and accurate MC-LR detection can be realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of detection technology, and specifically relates to a method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry. Background Art

[0002] Cyanobacterial harmful algal blooms (cHABs) may pose a serious threat to public health because large amounts of cyanobacteria release a wealth of toxins into water bodies, especially microcystin-LR (MC-LR), which poses a potential health risk. Previous studies have shown that long-term exposure to low doses of MC-LR can cause serious damage to the liver, gonads, kidneys, digestive system, and nervous system in mice and humans. Due to its toxic effects, the International Agency for Research on Cancer classified MC-LR as a Class 2B carcinogen in 2010. MC-LR is widely present in natural water bodies. The detection rates of MC-LR in lakes and reservoirs in my country are 59% and 37%, respectively. For example, the average concentration of MC-LR in Dianchi Lake can reach 23.06 µg / L, and the concentration in Chaohu Lake can reach 26.7 µg / L. Aquatic organisms, mammals, and humans can be exposed to MC-LR through drinking water, eating aquatic products, contacting environmental waters, and participating in water recreational activities.

[0003] Early toxicokinetic experiments showed that after MC-LR enters the body, most of it is excreted in the feces and urine in the form of the original form, and only a small part is metabolized by the liver and then excreted in the feces and urine in the form of metabolites. Urine is one of the important pathways for MC-LR excretion. Currently, MC-LR has been found in the urine of mammals and humans with acute and chronic exposure, and the content of MC-LR in urine is the highest during acute exposure. Therefore, the presence of MC-LR in urine can be used as a biomarker for MC-LR exposure.

[0004] Among the existing methods for detecting algal toxins in urine, studies that can identify MC-LR all use mass spectrometry, which reflects the advantages of mass spectrometry technology, but these studies only test the urine of mammals that are acutely or chronically exposed to algal toxins to validate their methods. Due to differences between species and different exposure doses, it remains questionable whether these methods are applicable to humans. Another study developed an immunocapture protein phosphatase 2A assay (IC-PPIA) (Wharton RE. Quantification of Microcystin-LR in Human Urineby ImmunocaptureLiquid Chromatography Tandem Mass Spectrometry. doi: 10.1021 / acs.chemrestox.8b00126) to detect the total MCs concentration in the urine of residents living in cyanobacterial bloom areas. Previous studies have shown that it seems to take a long time, up to several weeks, to eliminate MCs. Considering the exposure risk of residents in cyanobacterial bloom areas and the risk of false positives in IC-PPIA that MC analogs may be mistaken for MC-LR, MCs should theoretically be widely present in their urine samples. However, the results were not ideal, with only 3 of the 86 urine samples testing positive.

[0005] In summary, current research on MC-LR detection in human urine still faces limitations in species differences, method specificity, and detection sensitivity. It is crucial to develop a rapid and accurate analytical technique to detect MC-LR in human urine. Summary of the invention

[0006] In view of the above technical problems, the present invention proposes a method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry, so as to improve the applicability and accuracy of the existing treatment methods for human urine.

[0007] In order to achieve the above object, the technical solution of the present invention is achieved as follows: A method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry comprises the following steps: (1) preparing a microcystin-LR standard aqueous solution; performing UPLC-MS / MS analysis on the standard aqueous solution; and establishing a standard curve of the concentration of the microcystin-LR standard aqueous solution corresponding to the peak area; (2) Treat the urine sample, take the urine supernatant for solid phase extraction, wash it with ultrapure water and methanol aqueous solution respectively, then elute it with high concentration methanol solution and blow dry it with nitrogen gas; (3) The product obtained in step (2) was re-dissolved in pure methanol solution and then concentrated under vacuum, and then re-dissolved in ultrapure water and centrifuged to obtain the supernatant for UPLC-MS / MS analysis; (4) The peak area corresponding to microcystin-LR in the urine sample obtained by UPLC-MS / MS analysis was used to calculate the concentration of microcystin-LR in urine based on the standard curve.

[0008] The urine sample is processed in step (2) as follows: the urine is heated in a water bath overnight, and the urine sample is centrifuged the next day to obtain a urine sample supernatant.

[0009] The solid phase extraction in step (2) is specifically performed by using an HLB solid phase extraction column. The HLB column is first activated with pure methanol and then balanced with ultrapure water. When the ultrapure water is lower than the upper layer of the extraction column, the urine sample is added and naturally passed through the column.

[0010] In the step (2), the concentration of the methanol aqueous solution during the elution process is 20%-30%, and the concentration of the methanol aqueous solution during the elution process is 80%-100%.

[0011] In the step (2), 0.1% formic acid is added to the methanol-water solution during the elution process; the water bath temperature during nitrogen drying is 55-65°C.

[0012] The vacuum concentration temperature in step (3) is 30-60°C; the volume of the urine sample reconstituted with ultrapure water is 1 / 20-1 / 50 of the original urine sample volume.

[0013] The conditions for the mass spectrometry analysis are: using an ESI+ ion source, mass spectrometry detection is in multiple reaction monitoring mode, the ion source temperature is 150°C, the desolvation gas temperature is 400-500°C, the desolvation gas flow rate is 800-1000 L / Hr, and the capillary voltage is 2.5-3.0 kV.

[0014] The conditions for the HPLC analysis are as follows: a C18 chromatographic column is selected as the chromatographic column, the mobile phase is 0.1% formic acid aqueous solution A and 0.1% formic acid acetonitrile B, the flow rate is 0.1 mL / min, and the column temperature of the chromatographic column is 30-60°C.

[0015] The elution gradient of the mobile phase for high performance liquid chromatography analysis is: The injection volume in the HPLC analysis is 5-10 µL; the minimum detection limit of the microcystin-LR is 1 ng / L.

[0016] The present invention has the following beneficial effects: The present invention establishes an ultra-high performance liquid chromatography-mass spectrometry tandem method (UPLC-MS / MS) for MC-LR, which can effectively separate it in the background of human urine matrix and implement high-throughput MC-LR detection to meet the demand for accurate quantification of MC-LR. The detection sensitivity is greatly improved by optimizing the mass spectrometry and chromatography.

[0017] The present invention can fill the gap in the existing human urine sample detection technology. It has been verified that the method has a LOD of ≥1 ng / L and a LOQ of ≥4 ng / L for MC-LR in urine, and has a good linear relationship within the linear range of 0.05-10 µg / L (r 2 ≥0.999) In addition, this method is highly practical and reproducible, with a verified recovery rate of 98.2-106% and a relative standard deviation (RSD) of 2.3-4.1%. This method can accurately quantify the concentration level of MC-LR in urine of the general population, and provide a new option for the detection of biomarkers of human MC-LR exposure in future epidemiological studies of microcystins. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0019] Figure 1 This is the chromatogram for the specific analysis in Example 1.

[0020] Figure 2 This is the linear relationship diagram of the MC-LR standard solution series.

[0021] Figure 3 This is the chromatogram of the standard MC-LR (concentration 0.05 μg / L).

[0022] Figure 4 The chromatographic separation patterns of MC-LR in urine samples of two random anonymous volunteers in Examples 1 and 2 are shown.

[0023] Figure 5 The chromatographic separation patterns of MC-LR in urine samples randomly sampled twice by an anonymous volunteer in Examples 3 and 4 are shown. DETAILED DESCRIPTION

[0024] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0025] Instruments and reagents used in the embodiments of the present invention: Ultra-high performance liquid chromatography triple quadrupole tandem mass spectrometer (Waters), including ACQUITY ultra-high performance liquid chromatography system, TQ-XS quadrupole mass spectrometer. Nitrogen blowdown device (NDK-24W, Guansen, China); vortex oscillator (VX-II, Scdeall, China), vacuum concentration centrifuge (eppendorf, Germany).

[0026] Methanol (LC / MS grade), acetonitrile (LC / MS grade), formic acid (LC / MS grade), ultrapure water, Oasis HLB column (3 cc / 60 mg).

[0027] Microcystin-LR standard was purchased from Taiwan Algae Science Co., Ltd., China, with a purity greater than 95%.

[0028] Embodiment 1: This embodiment provides a method for detecting the concentration of MC-LR in a urine sample, comprising the following steps: 1. Pre-treatment: 1) Place the urine to be tested in a 37°C water bath overnight, centrifuge for 30 min (4000 r / min, 4°C) the next day, and take the supernatant into a new centrifuge tube.

[0029] 2) Activation: Oasis HLB solid phase extraction column (3 cc / 60 mg) was activated with 3 mL of pure methanol before use.

[0030] 3) Balance: Use 3 mL of pure water for balance.

[0031] 4) Loading: When the pure water is lower than the upper layer of the extraction column, add 2 mL of urine; the sample passes through the column naturally.

[0032] 5) Elution: Gradient elution with 3 mL of pure water and 3 mL of methanol-water solution; the concentration of methanol-water solution is 20%.

[0033] 6) Elution: Use 6 mL of elution buffer.

[0034] Optionally, the solvent of the eluent is 80% methanol solution.

[0035] 7) Nitrogen blowing: Optionally, the water bath temperature of the nitrogen blowdown instrument is any temperature within the range of 65°C.

[0036] 8) Vacuum concentration: Add 0.5 mL of pure methanol to the centrifuge tube that has been blown almost dry with nitrogen, vortex and shake for 20-30 min to mix the solution, centrifuge at low speed (2000 r / min, 5 min), and transfer all the solution in the tube to a 1.5 mL centrifuge tube.

[0037] Optionally, the temperature of the vacuum concentrator is 60 °C.

[0038] 9) Reconstitution: Add 200 µL ultrapure water to reconstitute (1 / 20 of the original urine sample volume), centrifuge at high speed (16000 r / min, 10 min, 4 ℃), and take the supernatant into the instrument for analysis.

[0039] 2. UPLC-MS / MS detection: 1) Mass spectrometry conditions: ESI+ ion source and multiple reaction monitoring (MRM) mode were used to identify and quantify MC-LR.

[0040] Optional: collision energy 3 kv, ion source temperature 150 ℃, desolvation temperature 400 ℃, desolvation gas flow 800 L / h; parent ion / daughter ion pair selection 995.56 / 107.17 as the qualitative ion, 995.56 / 135.20 as the quantitative ion.

[0041] 2) Liquid phase conditions: Optionally, a Waters ACQUITY BEH C18 (2.1 mm×100 mm, 1.7 µm) column was used. After urine pretreatment, MC-LR was separated from other substances by liquid chromatography, and 0.1% formic acid water (A)-0.1% formic acid acetonitrile (B) was used as the mobile phase for gradient elution. The mobile phase gradient was: 0-0.5 min, 10% B; 0.5-6 min, 10%-60% B; 6-8 min, 60-80% B; 8-8.5 min, 80-100% B, where mobile phase A+B=100%.

[0042] Optimal: After comparing column pressure, peak width, and substance separation at different flow rates and column temperatures, the flow rate is 0.1 mL / min; the column temperature is 45 °C, and the injection volume is 10 µL.

[0043] 3. Establishment of a standard curve of the concentration of the microcystin-LR standard aqueous solution corresponding to the peak area of ​​the sample detection 1) The present invention adopts the method of high performance liquid chromatography-mass spectrometry, confirms by retention time and two pairs of ion pairs MC-LR, and then performs quantitative analysis based on the peak area of ​​the standard. In the actual sample detection process, a standard of known concentration is detected once every 25 samples for quality control. The specific operation is as follows: 2) Specificity analysis: Calibration and verification were performed using known standards to ensure that the mass spectrometric characteristics of the measured MC-LR were consistent with the known ones; secondly, the blank sample (ultrapure water) was subjected to the entire sample pretreatment process, including the use of the same instruments, equipment, and reagents; In addition, the target analyte at a known concentration was added to the blank matrix (urine) as spiked urine and analyzed together with the blank urine to check for the presence of interfering substances. This method was optimized by optimizing the HPLC conditions, and the results were as follows Figure 1 As shown, the ultrapure water sample is a straight line; the blue line is a blank urine sample, and the peak position is urine protein and other substances; the red line is a spiked urine liquid chromatography sample, and compared with the blank urine sample, there is an additional MC-LR peak at the peak position; it can be seen that the method of the present invention has a good separation between the analyte MC-LR and other impurities in urine, and the separation degree R S >1.5, will not interfere with the analysis results of the target MC-LR.

[0044] The blank sample in the experiment had no interfering signal compared with the standard solution.

[0045] 3) Determination of standard curve and minimum detection limit: add 0.05 μg / L, 0.1 μg / L, 0.5 μg / L, 1 μg / L, 5 μg / L, and 10 μg / L standard solutions to ultrapure water, and inject 10 μl for UPLC-MS / MS analysis. Perform linear regression analysis on the peak area (Y) and concentration (X) of microcystin-LR to obtain the standard curve.

[0046] The results showed that the concentration of microcystin-LR substance showed a good linear relationship with the peak area relative to the internal standard, and the correlation coefficient (r 2 ) is greater than 0.999. The specific equation and correlation coefficient are as follows: Figure 2 As shown, the standard curve equation is: Y=9942.07*X+(-101.375).

[0047] Figure 3 The following is the chromatogram of the standard sample of MC-LR (concentration 0.05 μg / L). The minimum detection limit (LOD) of MC-LR was calculated to be 1 ng / L based on the signal-to-noise ratio (S / N).

[0048] 4. Determine the concentration of Microcystin-LR in human urine samples: 1) Substitute the peak area corresponding to microcystin-LR in the urine sample obtained by UPLC-MS / MS analysis into the standard curve to calculate the concentration of microcystin-LR in urine.

[0049] 2) Measurement of actual samples: MC-LR in actual urine of anonymous adult volunteers was measured, and the urine chromatogram of one volunteer was randomly selected for testing. The results are as follows: Figure 4 As shown (black curve); the measured MC-LR concentration was 0.087 μg / L.

[0050] 3) Determination of recovery and repeatability: Standard samples with certain concentrations of 0.05, 0.1, and 0.5 μg / L were added to the blank matrix, and the samples were tested according to the sample pretreatment and instrumental analysis methods. The recovery of the method (the ratio of the average value of the measured concentration to the theoretical concentration) was calculated. Three groups of parallel samples were prepared for each concentration, and the reproducibility of the method was calculated based on the average value of the three test results for each concentration. The results showed that in the urine matrix, the recovery of MC-LR (the ratio of the average value of the measured concentration to the theoretical concentration) was 98.2-106%, and the relative standard deviation (RSD=[(single measurement value-average value) / average value]×100%) was 2.3-4.1%.

[0051] Example 2 This embodiment provides a method for detecting the concentration of MC-LR in a urine sample, comprising the following steps: 1. Pre-treatment: 1) Place the urine to be tested in a 37°C water bath overnight, centrifuge for 30 min (4000 r / min, 4°C) the next day, and take the supernatant into a new centrifuge tube.

[0052] 2) Activation: Oasis HLB solid phase extraction column (3 cc / 60 mg) was activated with 3 mL of pure methanol before use.

[0053] 3) Balance: Use 3 mL of pure water for balance.

[0054] 4) Loading: When the pure water is lower than the upper layer of the extraction column, add 2 mL of urine; the sample passes through the column naturally.

[0055] 5) Elution: Gradient elution with 3 mL of pure water and 3 mL of methanol-water solution; the concentration of methanol-water solution is 30%.

[0056] 6) Elution: Use 6 mL of elution buffer.

[0057] Optionally, the solvent of the eluent is 90% methanol solution.

[0058] 7) Nitrogen blowing: Optionally, the water bath temperature of the nitrogen blowdown instrument is 55 °C.

[0059] 8) Vacuum concentration: Add 0.5 mL of pure methanol to the centrifuge tube that has been blown almost dry with nitrogen, vortex and shake for 20-30 min to mix the solution, centrifuge at low speed (1800 r / min, 5 min), and transfer all the solution in the tube to a 1.5 mL centrifuge tube.

[0060] Optionally, the temperature of the vacuum concentrator is 45 °C.

[0061] 9) Reconstitution: Add 200 µL ultrapure water to reconstitute (1 / 20 of the original urine sample volume), centrifuge at high speed (10,000 r / min, 10 min, 4 °C), and take the supernatant into the instrument for analysis.

[0062] 2. UPLC-MS / MS detection: 1) Mass spectrometry conditions: ESI+ ion source and multiple reaction monitoring (MRM) mode were used to identify and quantify MC-LR.

[0063] Optional: collision energy 3.0 kV, ion source temperature 150 °C, desolvation temperature 500 °C, desolvation gas flow 1000 L / h; parent ion / daughter ion pair selection 995.56 / 107.17 as the qualitative ion, 995.56 / 135.20 as the quantitative ion.

[0064] 2) Liquid phase conditions: Optionally, a Waters ACQUITY BEH C18 (2.1 mm×100 mm, 1.7 µm) column was used. After urine pretreatment, MC-LR was separated from other substances by liquid chromatography, and 0.1% formic acid water (A)-0.1% formic acid acetonitrile (B) was used as the mobile phase for gradient elution. The mobile phase gradient was: 0-0.5 min, 10% B; 0.5-6 min, 10%% B; 6-8 min, 60% B; 8-8.5 min, 80% B, where A+B=100% in the mobile phase.

[0065] Optimal: After comparing column pressure, peak width, and substance separation at different flow rates and column temperatures, the flow rate is 0.1 mL / min; the column temperature is 45 °C, and the injection volume is 10 µL.

[0066] 3. The steps for sample detection and standard curve establishment are the same as those in Example 1; The concentration of the substance showed a good linear relationship with the peak area measured relative to the internal standard, and the correlation coefficient (r 2 ) was greater than 0.999. The lowest limit of detection (LOD) of MC-LR was calculated to be 1 ng / L based on the signal-to-noise ratio (S / N).

[0067] 4. Determine the concentration of Microcystin-LR in the human urine sample to be tested: 1) Substitute the peak area corresponding to microcystin-LR in the urine sample obtained by UPLC-MS / MS analysis into the standard curve to calculate the concentration of microcystin-LR in urine.

[0068] 2) Determination of recovery and repeatability: Standard samples at certain concentrations of 0.05, 0.1, and 0.5 μg / L were added to the blank matrix, and the samples were tested according to the sample pretreatment and instrumental analysis methods. The recovery of the method was calculated. Three groups of parallel samples were prepared for each concentration, and the reproducibility of the method was calculated as the average of the three test results for each concentration. The results showed that in the urine matrix, the recovery of MC-LR was 98.2-106%, and the relative standard deviation (RSD) was 2.3-4.1%.

[0069] 3) Measurement of actual samples: MC-LR in actual urine of anonymous adult volunteers was measured, and the urine chromatogram of another anonymous volunteer was randomly selected for testing. The results are as follows: Figure 4 As shown (blue curve); the measured MC-LR concentration was 0.032 μg / L.

[0070] Example 3 This embodiment provides a method for detecting the concentration of MC-LR in a urine sample, comprising the following steps: 1. Pre-treatment: 1) Place the urine to be tested in a 37°C water bath overnight, centrifuge it the next day for 25 min (4000 r / min, 4°C), and take the supernatant into a new centrifuge tube.

[0071] 2) Activation: Oasis HLB solid phase extraction column (3 cc / 60 mg) was activated with 3 mL of pure methanol before use.

[0072] 3) Balance: Use 3 mL of pure water for balance.

[0073] 4) Loading: When the pure water is lower than the upper layer of the extraction column, add 2 mL of urine; the sample passes through the column naturally.

[0074] 5) Elution: Gradient elution with 3 mL of pure water and 3 mL of methanol-water solution; the concentration of methanol-water solution is 25%.

[0075] 6) Elution: Use 6 mL of elution buffer.

[0076] Optionally, the solvent of the eluent is 100% methanol solution.

[0077] 7) Nitrogen blowing: Optionally, the water bath temperature of the nitrogen blowdown instrument is any temperature within the range of 60°C.

[0078] 8) Vacuum concentration: Add 0.5 mL of pure methanol to the centrifuge tube that has been blown almost dry with nitrogen, vortex and shake for 20-30 min to mix the solution, centrifuge at low speed (1900 r / min, 5 min), and transfer all the solution in the tube to a 1.5 mL centrifuge tube.

[0079] Optionally, the temperature of the vacuum concentrator is 30°C.

[0080] 9) Reconstitution: Add 200 µL ultrapure water to reconstitute (1 / 30 of the original urine sample volume), centrifuge at high speed (14000 r / min, 10 min, 4 ℃), and take the supernatant into the instrument for analysis.

[0081] 2. UPLC-MS / MS detection: 1) Mass spectrometry conditions: ESI+ ion source and multiple reaction monitoring (MRM) mode were used to identify and quantify MC-LR.

[0082] Optional: collision energy 2.5 kv, ion source temperature 150 ℃, desolvation temperature 450 ℃, desolvation gas flow 900 L / h; parent ion / daughter ion pair selection 995.56 / 107.17 as the qualitative ion, 995.56 / 135.20 as the quantitative ion.

[0083] 2) Liquid phase conditions: Optionally, a Waters ACQUITY BEH C18 (2.1 mm×100 mm, 1.7 µm) column was used. After urine pretreatment, MC-LR was separated from other substances by liquid chromatography, and 0.1% formic acid water (A)-0.1% formic acid acetonitrile (B) was used as the mobile phase for gradient elution. The mobile phase gradient was: 0-0.5 min, 10% B; 0.5-6 min, 60% B; 6-8 min 80% B; 8-8.5 min, 100% B, where A+B=100%.

[0084] Optimal: After comparing column pressure, peak width, and substance separation at different flow rates and column temperatures, the flow rate is 0.1 mL / min; the column temperature is 45 °C, and the injection volume is 10 µL.

[0085] 3. The method of sample detection and standard curve establishment is the same as that in Example 1; 4. Determine the concentration of Microcystin-LR in human urine samples: 1) Substitute the peak area corresponding to microcystin-LR in the urine sample obtained by UPLC-MS / MS analysis into the standard curve to calculate the concentration of microcystin-LR in urine. The actual urine MC-LR of anonymous adult volunteers was measured, and the MC-LR concentration was measured to be 0.36 μg / L through the urine detection chromatogram. Figure 5 shown.

[0086] 2) Determination of recovery and repeatability: Standard samples at certain concentrations of 0.05, 0.1, and 0.5 μg / L were added to the blank matrix, and the samples were tested according to the sample pretreatment and instrumental analysis methods. The recovery of the method was calculated. Three groups of parallel samples were prepared for each concentration, and the reproducibility of the method was calculated using the average of the three test results for each concentration. The results showed that in the urine matrix, the recovery of MC-LR was 97-108%, and the relative standard deviation (RSD) was 2.0-4.5%.

[0087] Embodiment 4: This embodiment provides a method for determining the concentration of MC-LR in a urine sample by liquid chromatography-mass spectrometry, comprising the following steps: 1. Pre-treatment: 1) Place the urine to be tested in a 37°C water bath overnight, centrifuge for 30 min (4000 r / min, 4°C) the next day, and take the supernatant into a new centrifuge tube.

[0088] 2) Activation: Oasis HLB solid phase extraction column (3 cc / 60 mg) was activated with 3 mL of pure methanol before use.

[0089] 3) Balance: Use 3 mL of pure water for balance.

[0090] 4) Loading: When the pure water is lower than the upper layer of the extraction column, add 2 mL of urine; the sample passes through the column naturally.

[0091] 5) Elution: Gradient elution with 3 mL of pure water and 3 mL of methanol-water solution; the concentration of methanol-water solution is 30%.

[0092] 6) Elution: Use 6 mL of elution buffer.

[0093] Optionally, the solvent of the eluent is 80% methanol aqueous solution containing 0.1% formic acid.

[0094] 7) Nitrogen blowing: The water bath temperature of the nitrogen blowdown instrument is any temperature within the range of 60 ℃.

[0095] 8) Vacuum concentration: Add 0.5 mL of pure methanol to the centrifuge tube that has been blown almost dry with nitrogen, vortex and shake for 20 min to mix the solution, centrifuge at low speed (2000 r / min, 5 min), and transfer all the solution in the tube to a 1.5 mL centrifuge tube.

[0096] Optionally, the temperature of the vacuum concentrator is 45°C.

[0097] 9) Reconstitution: Add 200 µL ultrapure water to reconstitute (1 / 40 of the original urine sample volume), centrifuge at high speed (12000 r / min, 10 min, 4 ℃), and take the supernatant into the instrument for analysis.

[0098] 2. UPLC-MS / MS detection: 1) Mass spectrometry conditions: ESI+ ion source and multiple reaction monitoring (MRM) mode were used to identify and quantify MC-LR.

[0099] Optional: collision energy 3.0 kV, ion source temperature 150 ℃, desolvation temperature 450 ℃, desolvation gas flow 1000 L / h; parent ion / daughter ion pair selection 995.56 / 107.17 as the qualitative ion, 995.56 / 135.20 as the quantitative ion.

[0100] 2) Liquid phase conditions: Optionally, a Waters ACQUITY BEH C18 (2.1 mm×100 mm, 1.7 µm) column was used. After urine pretreatment, MC-LR was separated from other substances by liquid chromatography, and 0.1% formic acid water (A)-0.1% formic acid acetonitrile (B) was used as the mobile phase for gradient elution. The mobile phase gradient was: 0-0.5 min, 10% B; 0.5-6 min, 10%-60% B; 6-8 min, 60-80% B; 8-8.5 min, 80-100% B, where A+B=100%.

[0101] Optimal: After comparing column pressure, peak width, and substance separation at different flow rates and column temperatures, the flow rate is 0.1 mL / min; the column temperature is 45 °C, and the injection volume is 10 µL.

[0102] 3. The method of sample detection and standard curve establishment is the same as that in Example 1; 4. Determine the concentration of Microcystin-LR in human urine samples: 1) Substitute the peak area corresponding to microcystin-LR in the urine sample obtained by UPLC-MS / MS analysis into the standard curve to calculate the concentration of microcystin-LR in urine. For the measurement of MC-LR in urine of the same volunteer at different time points in Example 3, the MC-LR concentration was measured to be 0.014 μg / L through the urine detection chromatogram. Figure 5 shown.

[0103] 2) Determination of recovery and repeatability: Standard samples at certain concentrations of 0.05, 0.1, and 0.5 μg / L were added to the blank matrix, and the samples were tested according to the sample pretreatment and instrumental analysis methods. The recovery of the method was calculated. Three groups of parallel samples were prepared for each concentration, and the reproducibility of the method was calculated using the average of the three test results for each concentration. The results showed that in the urine matrix, the recovery of MC-LR was 102-115%, and the relative standard deviation (RSD) was 2.0-4.6%.

[0104] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry. It is characterized in that The steps include: (1) preparing a microcystin-LR standard aqueous solution; performing UPLC-MS / MS analysis on the standard aqueous solution; and establishing a standard curve of the concentration of the microcystin-LR standard aqueous solution corresponding to the peak area; (2) Treat the urine sample, take the urine sample supernatant for solid phase extraction, wash with ultrapure water and methanol aqueous solution respectively, then elute with high concentration methanol solution and blow dry with nitrogen; (3) The product obtained in step (2) was re-dissolved in pure methanol solution and then concentrated under vacuum, and then re-dissolved in ultrapure water and centrifuged to obtain the supernatant for UPLC-MS / MS analysis; (4) The peak area corresponding to MC-LR in urine obtained by UPLC-MS / MS analysis was used to calculate the concentration of MC-LR in urine based on the standard curve.

2. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 1, It is characterized in that The urine sample is processed in step (2) as follows: the urine is heated in a water bath overnight, and the urine sample is centrifuged the next day to obtain a urine sample supernatant.

3. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 2, It is characterized in that The solid phase extraction in step (2) is specifically performed by using an HLB solid phase extraction column. The HLB column is first activated with pure methanol and then balanced with ultrapure water. When the ultrapure water is lower than the upper layer of the extraction column, the urine sample is added and naturally passed through the column.

4. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to any one of claims 1 to 3, It is characterized in that In the step (2), the concentration of the methanol aqueous solution during the elution process is 20%-30%, and the concentration of the methanol aqueous solution during the elution process is 80%-100%.

5. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 4, It is characterized in that During the elution process in step (2), 0.1% formic acid is added to the methanol aqueous solution; and the water bath temperature during nitrogen drying is 55-65°C.

6. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 4, It is characterized in that The vacuum concentration temperature in step (3) is 30-60°C; the volume of the urine sample reconstituted with ultrapure water is 1 / 20-1 / 50 of the original urine sample volume.

7. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 4, It is characterized in that The conditions for the mass spectrometry analysis are: using an ESI+ ion source, mass spectrometry detection is in multiple reaction monitoring mode, the ion source temperature is 150°C, the desolvation gas temperature is 400-500°C, the desolvation gas flow rate is 800-1000 L / Hr, and the capillary voltage is 2.5-3.0 kV.

8. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 4, It is characterized in that The conditions for the HPLC analysis are as follows: a C18 chromatographic column is selected as the chromatographic column, the mobile phase is 0.1% formic acid aqueous solution A and 0.1% formic acid acetonitrile B, the flow rate is 0.1 mL / min, and the column temperature of the chromatographic column is 30-60°C.

9. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 8, It is characterized in that The elution gradient of the mobile phase for high performance liquid chromatography analysis is: 。 10. The method for determining microcystin-LR in human urine by liquid chromatography-mass spectrometry according to claim 1, It is characterized in that The injection volume in the HPLC analysis is 5-10 µL; the minimum detection limit of the microcystin-LR is 1 ng / L.

Citation Information

Patent Citations

  • UPLC-MS / MS detecting method for detecting concentration of parabens preservatives in human urine

    CN106248834A

  • Method for detecting content of microcystic toxins in water by high pressure liquid chromatography-mass spectrometry

    CN114397384A

  • Method for simultaneously determining multiple deet insecticides, neonicotinoid insecticides and metabolites in urine

    CN116953104A

  • Protocol for Preconcentration and Quantification of Microcystins Using LC-MS

    US20180321237A1

Cited By

  • Application of FeTMPyP in preparation of medicine for relieving ovarian toxicity

    CN120241742A